The Experts below are selected from a list of 55650 Experts worldwide ranked by ideXlab platform
Carlos Iribarren - One of the best experts on this subject based on the ideXlab platform.
-
elevated blood pressure and risk of end stage renal disease in subjects without baseline kidney disease
JAMA Internal Medicine, 2005Co-Authors: Charles E Mcculloch, Jeanne Darbinian, Alan S Go, Carlos IribarrenAbstract:Background Many cases of end-stage renal disease (ESRD) are ascribed to hypertension. However, because renal disease itself can raise blood pressure, some investigators argue that ESRD seen in patients with hypertension is due to underlying primary renal disease. Previous cohort studies of the relationship between blood pressure and ESRD did not uniformly screen out baseline kidney disease. Methods We conducted a historical cohort study among members of Kaiser Permanente of Northern California, a large integrated health care delivery system. The ESRD cases were ascertained by matching with the US Renal Data System registry. Results A total of 316 675 adult Kaiser members participated in the Multiphasic Health Checkups from 1964 to 1985. All subjects had estimated glomerular filtration rates of 60 mL /min per 1.73 m 2 or higher and negative dipstick urinalysis results for proteinuria or hematuria. During 8 210 431 person-years of follow-up, 1149 cases of ESRD occurred. Compared with subjects with a blood pressure less than 120/80 mm Hg, the adjusted relative risks for developing ESRD were 1.62 (95% confidence interval [CI], 1.27-2.07) for blood pressures of 120 to 129/80 to 84 mm Hg, 1.98 (95% CI, 1.55-2.52) for blood pressures of 130 to 139/85 to 89 mm Hg, 2.59 (95% CI, 2.07-3.25) for blood pressures of 140 to 159/90 to 99 mm Hg, 3.86 (95% CI, 3.00-4.96) for blood pressures of 160 to 179/100 to 109 mm Hg, 3.88 (95% CI, 2.82-5.34) for blood pressures of 180 to 209/110 to 119 mm Hg, and 4.25 (95% CI, 2.63-6.86) for blood pressures of 210/120 mm Hg or higher. Similar associations between blood pressure level and ESRD risk were seen in all subgroup analyses. Conclusions Even relatively modest elevation in blood pressure is an independent risk factor for ESRD. The observed relationship does not appear to be due to confounding by clinically evident baseline kidney disease.
-
elevated blood pressure and risk of end stage renal disease in subjects without baseline kidney disease
JAMA Internal Medicine, 2005Co-Authors: Chiyuan Hsu, Charles E Mcculloch, Jeanne Darbinian, Carlos IribarrenAbstract:Background Many cases of end-stage renal disease (ESRD) are ascribed to hypertension. However, because renal disease itself can raise blood pressure, some investigators argue that ESRD seen in patients with hypertension is due to underlying primary renal disease. Previous cohort studies of the relationship between blood pressure and ESRD did not uniformly screen out baseline kidney disease. Methods We conducted a historical cohort study among members of Kaiser Permanente of Northern California, a large integrated health care delivery system. The ESRD cases were ascertained by matching with the US Renal Data System registry. Results A total of 316 675 adult Kaiser members participated in the Multiphasic Health Checkups from 1964 to 1985. All subjects had estimated glomerular filtration rates of 60 mL /min per 1.73 m 2 or higher and negative dipstick urinalysis results for proteinuria or hematuria. During 8 210 431 person-years of follow-up, 1149 cases of ESRD occurred. Compared with subjects with a blood pressure less than 120/80 mm Hg, the adjusted relative risks for developing ESRD were 1.62 (95% confidence interval [CI], 1.27-2.07) for blood pressures of 120 to 129/80 to 84 mm Hg, 1.98 (95% CI, 1.55-2.52) for blood pressures of 130 to 139/85 to 89 mm Hg, 2.59 (95% CI, 2.07-3.25) for blood pressures of 140 to 159/90 to 99 mm Hg, 3.86 (95% CI, 3.00-4.96) for blood pressures of 160 to 179/100 to 109 mm Hg, 3.88 (95% CI, 2.82-5.34) for blood pressures of 180 to 209/110 to 119 mm Hg, and 4.25 (95% CI, 2.63-6.86) for blood pressures of 210/120 mm Hg or higher. Similar associations between blood pressure level and ESRD risk were seen in all subgroup analyses. Conclusions Even relatively modest elevation in blood pressure is an independent risk factor for ESRD. The observed relationship does not appear to be due to confounding by clinically evident baseline kidney disease.
Lu Qinzhong - One of the best experts on this subject based on the ideXlab platform.
-
method for manufacturing artificial leather with superhard hand feeling
2013Co-Authors: Zhao Jianming, Cheng Feng, Lu QinzhongAbstract:The invention discloses a method for manufacturing artificial leather with superhard hand feeling. The method comprises stirring a polyvinyl chloride resin 100 parts, a plasticizer 30-50 parts, a filler 30-50 parts, a lubricant 0.5-1 part, a heat-resistant stabilizer 2-5 parts, a pigment 3-5 parts and a modifying agent 30-50 parts at 120-130 DEG C for 100-200 s; mixing in a Banbury mixer at 130-150 DEG C for 200-300 s; milling in a rubber mixing mill at 120-130 DEG C for 10-20 min; calendaring in a calendaring machine at 160-180 DEG C to generate a 0.4-0.6 mm sheet material and bonding with a calendaring base under the pressure higher than or equal to 1 T; and foaming in a foaming machine at 190-200 DEG C, embossing, cooling and shaping. The inventive method can obtain artificial leather with hard hand feeling, and has simple process and low manufacturing cost. The obtained artificial leather requires no additional support material in application.
-
method for manufacturing artificial leather with magnetic induction
2013Co-Authors: Zhao Jianming, Cheng Feng, Lu QinzhongAbstract:The invention discloses a method for manufacturing artificial leather with magnetic induction. The method comprises a polyvinyl chloride resin 100 parts, a plasticizer 30-100 parts, a filler 10-80 parts, a lubricant 0.5-1 part, a heat-resistant stabilizer 2-5 parts, a pigment 3-5 parts and a magnetic induction material 30-100 parts in a high-speed dispersing mixer at 120-130 DEG C. for 150-250 s; mixing in a Banbury mixer at 130-150 DEG C. for 200-300 s; milling in a rubber mixing mill at 120-130 DEG C. for 10-20 min; canlendering in a canlendering machine at 165-170 DEG C. to give a 0.4-0.6 mm sheet material and bonding the sheet material with a canlendering base under the pressure higher than or equal to 1 T; and foaming in a foaming machine at 180-190 DEG C., embossing and cooling. The invention can obtain artificial leather with magnetic attraction characteristics.
-
method for manufacturing surface wear resistant artificial leather
2013Co-Authors: Zhao Jianming, Cheng Feng, Lu QinzhongAbstract:The invention discloses a method for manufacturing surface wear-resistant artificial leather. The method comprises stirring a polyvinyl chloride resin 100 parts, a plasticizer 30-100 parts, a filler 10-80 parts, a lubricant 0.5-1 part, a heat-resistant stabilizer 2-5 parts, a pigment 3-5 parts, a modifying agent 1-10 parts, a processing auxiliary agent 3-15 parts and a wear-resistant modified material 30-50 parts in a high-speed dispersing mixer at 120-130 DEG C. for 100-200 s; mixing in a Banbury mixer at 130-150 DEG C. for 200-300 s; milling in a rubber mixing mill at 120-130 DEG C. for 10-20 min; canlendering at 160-180 DEG C. to give a 0.2-0.4 mm sheet material, and bonding the sheet material with a canlendering base under the pressure higher than or equal to 1 T; and foaming in a foaming machine at 190-200 DEG C., embossing and cooling. The inventive method can obtain artificial leather with wear resistance on the surface to avoid wear and prolong service life.
-
preparation method of impact resistant artificial leather
2012Co-Authors: Zhao Jianming, Cheng Feng, Lu QinzhongAbstract:The invention discloses a preparation method of an impact-resistant artificial leather, comprising the following steps of: stirring 100 parts of polrvinyl chloride resin, 30-100 parts of plasticizer, 10-80 parts of filler, 0.5-1 part of lubricant, 2-5 parts of heat-resistant stabilizer, 3-5 parts of pigment, 1-10 parts of regulating agent and 3-15 parts of processing agent for 100-200 seconds at the temperature of 120-130DEG C through a high-speed dispersing mixer; charging the mixture obtained in the former step into an internal mixer to mix for 200-300 seconds at the temperature of 130-150DEG C; and charging the product obtained in the former step into a rubber fining mixer for plastication for 10-20 minutes at the temperature of 120-130 DEG C; calendaring into a sheet material with 0.3-0.5mm by a calendar at the temperature of 150-170 DEG C, and fitting the sheet material and a calendaring base material, wherein a fitting pressure is larger than or equal to 1T; and charging into a foaming machine and heating to 190-205 DEG C, foaming, embossing and shaping in a cooling way. The surface of the impact-resistant artificial leather prepared by the method is good in an impact-resistant effect, so that the application range of the impact-resistant artificial leather prepared by the preparation method in the shoemaking and the ball products can be effectively expanded.
A.k. Al-suwailem - One of the best experts on this subject based on the ideXlab platform.
-
NAN-190, a possible specific antagonist for methamphetamine
Regulatory toxicology and pharmacology : RTP, 2004Co-Authors: O.t. Ginawi, Abdulhakeem A. Al-majed, A.k. Al-suwailemAbstract:Abstract Effect of NAN-190, a selective 5-HT 1A receptor antagonist, on methamphetamine-induced locomotor activity, anorexia, analgesia, and hyperthermia was investigated in male mice. Methamphetamine (1.5 mg/kg, i.p) produced a significant increase in locomotor activity, which was significantly antagonized by NAN-190 at a dose of 4 mg/kg, i.p. NAN-190 did not alter the antinociceptive activity of mice when it was administered alone. Methamphetamine (2 mg/kg, i.p) produced a significant decrease in food intake of mice, which were deprived of food during the previous 24 h. This anorectic activity of methamphetamine was significantly antagonized by NAN-190 at a dose of 2 mg/kg, i.p. NAN-190 did not alter the food intake of mice when it was administered alone. Methamphetamine (2 mg/kg, i.p) also produced a significant increase in body temperature of mice, which was significantly antagonized by NAN-190 at a dose of 0.5 mg/kg, i.p. NAN-190 did not alter the body temperature of mice when it was administered alone. In the writhing test, methamphetamine (1 mg/kg, i.p) produced a significant antinociceptive effect in mice. This was significantly antagonized by NAN-190 at a dose of 1 mg/kg, i.p. NAN-190 did not alter the antinociceptive activity of mice when it was administered alone. The results of the present study indicate a possible role for serotonergic mechanisms, in addition to the catecholaminergic systems, in the above-studied activities of methamphetamine in mice. This role is possibly mediated through direct stimulation of the 5-HT 1A receptor subtype. All of the above-studied activities of methamphetamine were antagonized by NAN-190, which may indicate that NAN-190 is a possible antagonist for methamphetamine.
Charles E Mcculloch - One of the best experts on this subject based on the ideXlab platform.
-
elevated blood pressure and risk of end stage renal disease in subjects without baseline kidney disease
JAMA Internal Medicine, 2005Co-Authors: Charles E Mcculloch, Jeanne Darbinian, Alan S Go, Carlos IribarrenAbstract:Background Many cases of end-stage renal disease (ESRD) are ascribed to hypertension. However, because renal disease itself can raise blood pressure, some investigators argue that ESRD seen in patients with hypertension is due to underlying primary renal disease. Previous cohort studies of the relationship between blood pressure and ESRD did not uniformly screen out baseline kidney disease. Methods We conducted a historical cohort study among members of Kaiser Permanente of Northern California, a large integrated health care delivery system. The ESRD cases were ascertained by matching with the US Renal Data System registry. Results A total of 316 675 adult Kaiser members participated in the Multiphasic Health Checkups from 1964 to 1985. All subjects had estimated glomerular filtration rates of 60 mL /min per 1.73 m 2 or higher and negative dipstick urinalysis results for proteinuria or hematuria. During 8 210 431 person-years of follow-up, 1149 cases of ESRD occurred. Compared with subjects with a blood pressure less than 120/80 mm Hg, the adjusted relative risks for developing ESRD were 1.62 (95% confidence interval [CI], 1.27-2.07) for blood pressures of 120 to 129/80 to 84 mm Hg, 1.98 (95% CI, 1.55-2.52) for blood pressures of 130 to 139/85 to 89 mm Hg, 2.59 (95% CI, 2.07-3.25) for blood pressures of 140 to 159/90 to 99 mm Hg, 3.86 (95% CI, 3.00-4.96) for blood pressures of 160 to 179/100 to 109 mm Hg, 3.88 (95% CI, 2.82-5.34) for blood pressures of 180 to 209/110 to 119 mm Hg, and 4.25 (95% CI, 2.63-6.86) for blood pressures of 210/120 mm Hg or higher. Similar associations between blood pressure level and ESRD risk were seen in all subgroup analyses. Conclusions Even relatively modest elevation in blood pressure is an independent risk factor for ESRD. The observed relationship does not appear to be due to confounding by clinically evident baseline kidney disease.
-
elevated blood pressure and risk of end stage renal disease in subjects without baseline kidney disease
JAMA Internal Medicine, 2005Co-Authors: Chiyuan Hsu, Charles E Mcculloch, Jeanne Darbinian, Carlos IribarrenAbstract:Background Many cases of end-stage renal disease (ESRD) are ascribed to hypertension. However, because renal disease itself can raise blood pressure, some investigators argue that ESRD seen in patients with hypertension is due to underlying primary renal disease. Previous cohort studies of the relationship between blood pressure and ESRD did not uniformly screen out baseline kidney disease. Methods We conducted a historical cohort study among members of Kaiser Permanente of Northern California, a large integrated health care delivery system. The ESRD cases were ascertained by matching with the US Renal Data System registry. Results A total of 316 675 adult Kaiser members participated in the Multiphasic Health Checkups from 1964 to 1985. All subjects had estimated glomerular filtration rates of 60 mL /min per 1.73 m 2 or higher and negative dipstick urinalysis results for proteinuria or hematuria. During 8 210 431 person-years of follow-up, 1149 cases of ESRD occurred. Compared with subjects with a blood pressure less than 120/80 mm Hg, the adjusted relative risks for developing ESRD were 1.62 (95% confidence interval [CI], 1.27-2.07) for blood pressures of 120 to 129/80 to 84 mm Hg, 1.98 (95% CI, 1.55-2.52) for blood pressures of 130 to 139/85 to 89 mm Hg, 2.59 (95% CI, 2.07-3.25) for blood pressures of 140 to 159/90 to 99 mm Hg, 3.86 (95% CI, 3.00-4.96) for blood pressures of 160 to 179/100 to 109 mm Hg, 3.88 (95% CI, 2.82-5.34) for blood pressures of 180 to 209/110 to 119 mm Hg, and 4.25 (95% CI, 2.63-6.86) for blood pressures of 210/120 mm Hg or higher. Similar associations between blood pressure level and ESRD risk were seen in all subgroup analyses. Conclusions Even relatively modest elevation in blood pressure is an independent risk factor for ESRD. The observed relationship does not appear to be due to confounding by clinically evident baseline kidney disease.
Maximiliano Ibarra - One of the best experts on this subject based on the ideXlab platform.
-
Evidence that NAN-190-induced hypotension involves vascular α1-adrenoceptor antagonism in the rat
European journal of pharmacology, 2002Co-Authors: Rafael Villalobos-molina, Itzell A. Gallardo-ortiz, J.javier López-guerrero, Maximiliano IbarraAbstract:The effect of NAN-190 (1-(2-methoxyphenyl)-4-[4-(2-phthalimido]-butyl] piperazine), described as a mixed 5-HT1A receptor agonist/antagonist, on cardiovascular function was studied. The i.v. injection of NAN-190 (1–300 μg/kg) dose-dependently decreased blood pressure (p
